Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4247-4253

  Rahko, Eeva ^a,b   Jukkola, Arja ^a   Melkko, Jukka ^a   Paavo, Pääkkö ^a   Bloigu, Risto ^a   Talvensaari Mattila, Anne ^a   Turpeenniemi Hujanen, Taina ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antiestrogen therapy; Breast carcinoma; MMP 9

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; GELATINASE B; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; TAMOXIFEN; TOREMIFENE;

EID: 14944362431     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Elwood JM, Cox B and Richardson AK: The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials 32: 1993.
2. EBCTCG: Polychemotherapy for early breast cancer, an overview of the randomized trials. Lancet 352: 930-42, 1998.
3. EBCTCG: Tamoxifen for early breast cancer: overview of the randomized trials. Lancet 351: 1451-67, 1998.
4. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinasis in metastasis. J Natl Cancer Inst 89: 1260-70, 1997
5. Duffy MJ and McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 12: 1343-48, 1998
6. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-62, 1998.
7. Talvensaari-Mattila A, Pääkkö P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89: 1270-5, 2003
8. Talvensaari-Mattila A, Pääkkö P, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65: 55-61, 2001
9. Cox G, Jones JL and O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349-55, 2000.
10. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B and Pantel K: Prognostic impact of matrix metalloproteinase-9 in operable non small cell lung cancer. Int J Cancer 103: 647-51, 2003.
11. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG and Taylor S: Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br 84: 706-11, 2002.
12. Remacle AG, Noel A, Duggan C, Mc Dermott E, O'Higgins N, Foidart JM and Duffy MJ: Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 77: 926-31, 1998.
13. Giannelli G, Fransvea E, Marinoschi F, Bergamini C, Daniele A, Colucci S, Paradiso A, Quaranta M and Antonaci S: Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun 292: 161-6, 2002.
14. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-51, 2003.
15. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T and Talieri M: Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84: 1488-96, 2001.
16. van't Veer Laura, Dai H, van de Vijver M, He Y, Hart A, Mao M, Peterse H, van der Kooy K, Marton M, Witteween A, Schreiber G, Kerkhoven R, Roberts C, Linsley P, Bernards R and Friend S: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
17. Kuittinen O, Soini Y and Turpeenniemi-Hujanen T: Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematology 69: 205-12, 2002.
18. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF and Mischel PS: Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 9: 2894-901, 2002.
19. Razandi M, Pedram A, Park ST and Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 4: 2701-12, 2003.
20. Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP and Karamanos NK: Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 2: 155-60, 2003.
21. Wolczynski S, Surazynski A, Swiatecka J and Palka J: Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol 3: 225-33, 2001.